Revenue - Schedule of Licensing, Royalties, and Other (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2026	Sep. 30, 2025	Sep. 30, 2026	Sep. 30, 2025
Revenue Recognition
Total revenue	$ 68,298	$ 70,445	$ 264,510	$ 976,340
Takeda
Revenue Recognition
Upfront payments	14,500		14,500
Unrecongnized consideration			4,000
Licensing, royalties, and other
Revenue Recognition
Total revenue	42,605	57,003	177,763	330,496
Database lock of an Existing Phase 2/3 clinical trial
Revenue Recognition
Upfront fee and milestones			500,000
Development, tech transfer, launch, and sales milestone payments			50,000
Sanofi \| Licensing, royalties, and other
Revenue Recognition
Total revenue	18,779	48,294	103,445	288,027
Sanofi \| Milestones
Revenue Recognition
Total revenue	0	0	0	175,000
Sanofi \| Royalties
Revenue Recognition
Total revenue	6,145	4,196	10,340	4,196
Sanofi \| Upfront fee amortization
Revenue Recognition
Total revenue	6,175	(1,083)	27,009	31,097
Sanofi \| Milestones amortization
Revenue Recognition
Total revenue	2,677	(645)	11,990	14,163
Sanofi \| Cost reimbursements
Revenue Recognition
Total revenue	3,782	45,826	54,106	63,571
Pfizer \| Licensing, royalties, and other
Revenue Recognition
Total revenue	0	0	30,000	0
Takeda \| Licensing, royalties, and other
Revenue Recognition
Total revenue	7,359	6,445	8,309	33,657
Serum \| Licensing, royalties, and other
Revenue Recognition
Total revenue	5,341	2,264	14,530	8,812
Other partners \| Licensing, royalties, and other
Revenue Recognition
Total revenue	11,126	0	21,479	0
Takeda \| Licensing, royalties, and other
Revenue Recognition
Total revenue	7,359	6,445	8,309	33,657
Takeda \| Upfront fee
Revenue Recognition
Total revenue	0	0	0	18,500
Takeda \| Milestones
Revenue Recognition
Total revenue	4,717	4,717	4,717	8,151
Takeda \| Royalties
Revenue Recognition
Total revenue	2,489	1,456	3,100	6,456
Takeda \| Support services
Revenue Recognition
Total revenue	$ 153	$ 272	$ 492	$ 550